Under en kontrolleret klinisk undersøgelse (n=195) var forekomsten af bivirkninger ikke højere hos forsøgspersoner, der fik begge de aktive indholdsstoffer samtidigt, end hos patienter i monoterapi.
During a controlled clinical study (n=195), the incidence of adverse reactions was not higher in subjects receiving both active substances concomitantly than in patients on monotherapy.